High grade serous carcinoma
Information
- Disease name
- High grade serous carcinoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03593681 | Completed | Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy | August 27, 2018 | February 14, 2020 | |
| NCT05490407 | Completed | N/A | Role of the ATP7A Transporter in Ovarian Cancer | March 17, 2021 | January 1, 2024 |
| NCT05537844 | Recruiting | Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma | October 27, 2021 | April 27, 2025 | |
| NCT04846933 | Recruiting | Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC | February 1, 2012 | December 2029 | |
| NCT05080556 | Recruiting | Phase 2 | Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer | May 24, 2023 | November 1, 2027 |
| NCT05358639 | Recruiting | Phase 1 | Combination of Olaparib and Navitoclax in Women With HGSC and TNBC | November 9, 2022 | April 28, 2025 |
| NCT03462342 | Recruiting | Phase 2 | Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer | March 9, 2018 | December 31, 2024 |
| NCT03824704 | Terminated | Phase 2 | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | August 23, 2019 | August 24, 2020 |
| NCT04598321 | Terminated | Phase 1 | BrUOG 390: Neoadjuvant Treatment With Talazoparib | March 29, 2021 | December 6, 2022 |
| NCT03738319 | Unknown status | Non-coding RNA in the Exosome of the Epithelia Ovarian Cancer | November 10, 2018 | November 23, 2019 | |
| NCT03509246 | Unknown status | Phase 2 | Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients | May 15, 2018 | March 2022 |
| NCT05390021 | Withdrawn | N/A | PET/MRI in Endometrial Cancer | March 30, 2024 | February 1, 2026 |